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Addiction is a chronic relapsing disorder hypothesized to be produced 
by drug-induced plasticity that renders individuals vulnerable to craving-
inducing stimuli such as re-exposure to the drug of abuse. Drug-induced 
plasticity that may result in the addiction phenotype includes increased 
excitatory signaling within corticostriatal pathways that correlates with 
craving in humans and is necessary for reinstatement in rodents. Reduced 
cystine–glutamate exchange by system xc– appears to contribute to 
heightened excitatory signaling within the striatum, thereby posing this as a 
novel target in the treatment of addiction. In the present report, we examined 
the impact of repeated N-acetyl cysteine, which is commonly used to activate 
cystine–glutamate exchange, on reinstatement in rodents in a preclinical 
study and on craving in cocaine-dependent humans in a preliminary, proof-of-
concept clinical experiment. Interestingly, repeated administration (7 days) of 
N-acetyl cysteine (60 mg/kg, IP) produced a significant reduction in cocaine 
(10 mg/kg, IP)-induced reinstatement, even though rats (N=10–12/group) 
were tested 24 h after the last administration of N-acetyl cysteine. The 
reduction in behavior despite the absence of the N-acetyl cysteine indicates 
that repeated N-acetyl cysteine may have altered drug-induced plasticity that 
underlies drug-seeking behavior. In parallel, our preliminary clinical data 
indicate that repeated administration (4 days) of N-acetyl cysteine (1200–
2400 mg/day) to cocaine-dependent human subjects (N=4 per group) 
produced a significant reduction in craving following an experimenter-
delivered IV injection of cocaine (20 mg/70 kg/60 s). Collectively, these data 
demonstrate that N-acetyl cysteine diminishes the motivational qualities of a 
cocaine challenge injection possibly by altering pathogenic drug-induced 
plasticity.  
 
Keywords: N-acetyl cysteine; cocaine; drug abuse; craving; reinstatement; 
cystine–glutamate exchange 
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Introduction 
 
The treatment of addiction to psychomotor stimulants is 
hindered by the lack of an FDA-approved pharmacotherapy. Obstacles 
to drug development include the limited number of therapeutic 
targets, the identification of which will likely require a more complete 
understanding of the neural basis of drug addiction. In particular, it is 
critical to understand how drug-induced plasticity gives rise to 
persistent drug craving when an individual is exposed to relapse-
inducing stimuli, such as acute exposure to the abused drug. 
 
Abnormal glutamate signaling within corticostriatal pathways 
represents an example of drug-induced neuroplasticity that may be 
pathological for compulsive drug craving and use, as it has been linked 
to craving in humans (Volkow et al, 2005) and reinstatement of 
extinguished drug seeking in rodents (Cornish and Kalivas, 2000; 
McFarland et al, 2003; Li et al, 2010; Xi et al, 2010). Extant data 
indicate that reduced cystine–glutamate exchange by system xc– may 
contribute to abnormal glutamate signaling within corticostriatal 
pathways and that cocaine-induced changes in system xc– are 
necessary for cocaine-induced reinstatement in rodents (Baker et al, 
2003; Madayag et al, 2007; Kau et al, 2008). Thus, system xc– has 
been proposed as a potential therapeutic target in the treatment of 
drug addiction.  
 
A second potential obstacle to the development of effective 
treatments for drug addiction is the predictive validity of existing 
animal models (Epstein and Preston, 2003; Katz and Higgins, 2003; 
Epstein et al, 2006; Yahyavi-Firouz-Abadi and See, 2009). A 
commonly used model is the reinstatement paradigm, whereby the 
capacity of discrete stimuli to reinstate extinguished operant 
responding on a lever that had been used to self-administer the 
abused substance is assessed. For example, N-acetyl cysteine, a 
cysteine prodrug used to drive system xc– was identified as a potential 
novel treatment for addiction, as acute administration blocked the 
capacity of an acute cocaine injection to reinstate extinguished cocaine 
seeking in rodents (Baker et al, 2003; Madayag et al, 2007; Kau et al, 
2008). What is unclear, however, is the impact of repeated 
N-acetyl cysteine on cocaine-induced reinstatement and cocaine-
induced craving in drug-dependent humans. This is important as 
repeated administration of N-acetyl cysteine results in reduced 
bioavailability (Pendyala and Creaven, 1995), yet would be the most 
likely method by which the drug would be delivered clinically. 
Moreover, the utility of this paradigm as a preclinical screen rests on 
the assumption that a reduction in the capacity of a discrete stimulus, 
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such as acute exposure to the self-administered drug, to reinstate 
extinguished drug seeking in rodents reflects a reduced motivation to 
obtain the abused drug that would be predictive of diminished drug 
craving in humans. The extent to which this is not the case raises 
questions regarding the translational utility as well as predictive 
validity of the reinstatement paradigm as a tool for preclinical 
screening of potential antiaddiction therapeutics. 
 
The primary goals of this study were to further evaluate the 
therapeutic potential of subchronic N-acetyl cysteine treatment and, in 
doing so, examine the predictive validity of the reinstatement 
paradigm. Specifically, we examined the impact of repeated 
administration of N-acetyl cysteine on cocaine intake and cocaine-
primed reinstatement in rodents and on self-reports of rush, high, and 
craving by nontreatment-seeking, cocaine-dependent human 
participants. 
 
Materials and Methods 
 
Rat Subjects 
 
Male Sprague Dawley rats (Harlan, Indianapolis, IN) weighing 
275–325 g upon arrival were individually housed in a temperature-
controlled colony room with a 12-h reversed light/dark cycle. Housing 
conditions and experimental protocols were approved by the 
institutional animal care and use committee of the Marquette 
University, and carried out according to the NIH Guide for the Care 
and Use of Laboratory Animals (1996). 
 
Rat Surgeries 
 
Rats were implanted with indwelling catheters under ketamine 
HCl (100 mg/kg, IP; Fort Dodge Animal Health, Fort Dodge, IA) and 
xylazine (2 mg/kg, IP; Lloyd Laboratories, Shenandoah, IA) anesthesia 
as previously described (Madayag et al, 2007; Kau et al, 2008). 
Following surgery, rats were given at least 5 days to recover before 
testing. 
 
Rat Cocaine Self-Administration Training 
 
Daily cocaine self-administration sessions occurred in operant 
conditioning chambers (ENV-008CT; MED-Associates, St Albans, VT) 
equipped with two retractable levers, two stimulus lights, and a water 
bottle and housed in sound attenuating cubicles (ENV-016M, MED-
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Associates) as previously described (Madayag et al, 2007; Kau et al, 
2008). In brief, rats underwent drug self-administration training during 
daily 2-h sessions in which operant responses on the active lever were 
reinforced with a cocaine infusion (0.5 mg/kg/200 ml IV; NIDA, 
Bethesda, MD) under an FR1 schedule of reinforcement. Each 
reinforced response resulted in the illumination of the stimulus light 
located above the active lever and was followed by a 25-s timeout 
period. Responding on a second lever designated as inactive and 
located on the back wall was recorded but had no programmed 
consequences. Once rats displayed stable rates of drug self-
administration, operationally defined <10% variation in daily 
responding over at least three consecutive sessions, they underwent 
12 daily maintenance sessions. 
 
Rat Extinction Training and Reinstatement Testing 
 
Following self-administration, rats remained in their home cages 
for 7 days before extinction training to ensure an adequate drug-free 
period before reinstatement, even if rats quickly extinguished. 
Extinction training involved placing rats into the operant chambers for 
2-h/day as described above, except that each active lever press now 
resulted in a saline infusion. This continued until the mean number of 
lever presses was ≤10 responses across at least three out of four 
sessions, at which point rats were tested for drug-primed 
reinstatement. Each rat underwent two reinstatement tests separated 
by 7 days. Each test was identical to the extinction sessions described 
above except that subjects received a cocaine injection (10 mg/kg, IP) 
immediately before being placed into the chamber. 
 
Rat N-acetyl Cysteine Treatment 
 
Rats received daily N-acetyl cysteine (0 or 60 mg/kg, IP; 
NAC) 60 min before daily maintenance self-administration sessions or 
during the 7 days separating the two reinstatement test days. 
 
Human Subjects 
 
A total of six right-handed (Oldfield, 1971) participants 
(4 males) meeting DSM-IV criteria for cocaine dependence, but 
otherwise healthy, were recruited from the general population via local 
advertisement. Subjects were excluded if they had an IQ <80, were 
positive for pregnancy, HIV, hepatitis, coagulopathy, neurological or 
hepatic illness, sulfa allergy, or concomitant or historical drug 
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dependence other than cocaine and nicotine. Participants were 
41.8±7.4 (mean±SD; range 28–49) years of age, had 18.3±4.0 
(12–20) years’ experience smoking crack cocaine with an age of first 
use of 21.0±4.2 (15–25) years, and were 8–48 h abstinent from 
cocaine by self-report and positive only for cocaine upon admission. All 
were exclusively crack cocaine users, four were one-pack/day cigarette 
smokers, and none met criteria for any other Axis I or II psychiatric 
disorder. Subjects underwent thorough medical and psychiatric 
screenings that included full blood and urine toxicology batteries and a 
12-lead electrocardiogram (ECG) to exclude cardiac abnormalities. 
Participants were counseled regarding the dangers of cocaine use by a 
study clinician and were offered the opportunity for cocaine 
detoxification and rehabilitation at each study visit; all declined 
treatment and continued to decline detoxification/rehabilitation offers 
throughout the study period. After a complete description of the study 
and viewing a video of General Clinical Research Center (GCRC) study 
procedures, subjects provided written informed consent to the Medical 
College of Wisconsin (MCW) IRB-approved protocol. 
 
Participants first underwent a drug ‘run-up’ procedure to 
become acquainted with the procedure, experienced a 20 mg/70 kg/60 
s IV dose of clinician-delivered cocaine in a controlled setting where 
their individual responses could be closely monitored and where any 
emergency interventions could be immediately applied. An Advanced 
Cardiac Life Support (ACLS)-certified clinician, support staff, and 
emergency equipment were present and available at all experimental 
sessions. This dose of cocaine has been used safely in other studies 
and approximates, or is slightly less, than the ‘high’ induced by a 
single use of crack cocaine reported by participants in our previous 
studies (Breiter et al, 1997; Li et al, 2000; Kufahl et al, 2005). ECG, 
heart rate, and pulse oximetry were monitored continuously and an 
auto-inflatable cuff monitored blood pressure at 2-min intervals. 
Cocaine delivery was withheld if the heart rate exceeded 120 
beats/min, if systolic blood pressure was >160mmHg, or if diastolic 
blood pressure was >100mmHg. 
 
Human Drug Treatment 
 
Participants remained inpatient for 1 to 2 separate 4-day/3-
night stays, each with one blinded, oral study medication: N-acetyl 
cysteine (400 or 800 mg TID, total daily dose 1200 or 2400 mg; N=4) 
or baclofen (20 mg TID, total daily dose 60 mg; N=4) (Panorama 
Compounding, Van Nuys, CA). There were no differences in the 
responses of the participants receiving 400 or 800 mg N-acetyl 
cysteine; thus, these data were pooled to increase the power of the 
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statistics. Participants received nine doses of the study medications 
with TID dosing on days 2 and 3 and 1 to 2 doses on day 1 (depending 
on when they completed the predrug test session) and day 4 (2–4 h 
before the postdrug test session; see Figure 1). 
 
Human Test Sessions 
 
During each 4-day visit, participants underwent separate test 
sessions on days 1 and 4 (pre- and post-drug treatment). Each test 
consisted of a 1-h session with three stimulus epochs, each starting 
with a 3- to 5-min baseline period designed to permit the 
determination of the capacity of each of the stimuli to induce high, 
rush, and craving. Cue-induction of high, rush, and craving was 
assessed during the first two epochs in which participants were 
exposed to a 4-min ‘neutral’ video depicting nonaffective, household 
scenes and a 4-min cocaine video depicting two cocaine-experienced 
males seated at a table simulating the use of crack cocaine. Drug 
induction of high, rush, and craving was assessed during the third 
epoch, in which participants received a cocaine infusion (20 mg/70 kg, 
IV) delivered in a volume of 10 ml/60 s in order to minimize the acute 
hedonic effect while maximizing drug craving (Abreu et al, 2001; 
Nelson et al, 2006). Subjects had an IV catheter inserted into the left 
forearm for drug delivery and the right forearm for drawing blood 
samples and as an alternate access site if needed. During the baseline 
and stimulus periods, participants completed visual analog scale (VAS) 
ratings of high, rush, and craving (Kufahl et al, 2005) resulting in 3–5 
1-min ratings during each baseline, five 1-min ratings during the 
neutral and cocaine videos, and 10 1-min ratings following the cocaine 
infusion, as described below. A 5-min, two-back, visuospatial working 
memory (VSWM; see below) task was completed after each video with 
the goal of engaging working memory in order to reduce residual drug 
euphoria and craving. 
 
Human Behavioral Ratings 
 
Subjects were instructed to rate their current level of high 
(while viewing the word ‘HIGH’ through prism glasses on a back-
projected screen), rush (‘RUSH’), and craving (‘CRAVING’) once every 
minute throughout the entire experiment, except during two 5-min 
VSWM periods. Participants were instructed to use their common 
‘street’ definitions for the constructs above. Questions cycled in a fixed 
order and remained on screen until answered or for a maximum of 15 
s. Subjects recorded their behavioral VAS ratings by using a joystick 
manipulandum to move a tab along a horizontal bar with anchors 
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‘Least Ever’ and ‘Most Ever’ at extrema and pushing a button at the 
desired rating. 
 
Human VSWM Task 
 
To cognitively engage the participant and distract from the 
internal hedonic or craving state in an attempt to return craving to 
baseline, a two-back VSWM task was incorporated into the session 
following each of the neutral and cocaine-related videos. In brief, the 
‘Bouncing Boxes’ task consisted of 30 s on/30 s off blocks for 5 min 
that requires a constant update of the working memory register and 
constant engagement. This task was targeted at ~80% correct 
responses, is amenable to training, and shows minimal practice effect; 
however, it is not based on fund of knowledge. 
 
Statistical Methods 
 
The SPSS statistics package (v17) was used to perform the 
statistical analyses. The data were analyzed using ANOVA with drug 
treatment (eg, dose of N-acetyl cysteine) as a between-subject factor, 
and time (time, day, or phase of the experiment) as a repeated factor. 
Significant main effects and interactions were further evaluated using 
Student’s t-tests as comparisons involved only two groups. Because 
our goal was to examine the impact of N-acetyl cysteine on evoked 
craving, rush, and high, basal values for these measures collected 
immediately before each phase of the experiment were subtracted 
from the values obtained during/after the neutral video, drug video, 
and cocaine infusion (see Table 1 for baseline values). Furthermore, 
deconstruction of interactions obtained in the analysis of the human 
data was restricted to reveal an effect of day (pre- or post-drug 
treatment) or drug treatment to minimize the number of comparisons. 
 
Results 
 
Daily N-acetyl Cysteine Treatment Does Not Alter the 
Reinforcing or Euphoric Properties of Cocaine  
 
Figure 2 illustrates that N-acetyl cysteine administered before 
daily sessions of cocaine self-administration does not alter cocaine 
intake in rodents. An ANOVA comparing daily cocaine intake with 
treatment (saline or N-acetyl cysteine) as a between-subject variable 
and infusion number during each daily session as a within-subject 
variable did not yield a significant interaction (F11, 132=0.644, =0.79), 
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main effect of time (F11, 132=0.505, =0.90), or main effect of 
treatment (F1, 12=0.43, =0.525). 
 
In cocaine-dependent human participants, repeated N-acetyl 
cysteine administration did not alter self-reports of cocaine-induced 
rush or high. Figure 3 illustrates evoked high or rush (difference from 
respective baseline that preceded each stimulus) reported during the 
presentation of the neutral video, drug video, or following an infusion 
of cocaine on test day 1 (predrug test) and test day 2 (postdrug test). 
An ANOVA comparing evoked rush with drug treatment (baclofen or N-
acetyl cysteine) as a between-subject factor and test day and phase of 
the experiment as repeated-measures variables failed to produce a 
significant three-way interaction (F2, 12=0.054, =0.947), but yielded 
an interaction between drug treatment and experimental phase (F2, 
12=4.3, =0.039). Deconstruction of the two-way interaction failed to 
produce a significant effect involving treatment, indicating a lack of an 
effect of N-acetyl cysteine or baclofen on self-reports of rush (see 
Figure 3a). An ANOVA comparing evoked high with drug treatment as 
a between-subject factor and test day and phase of the experiment as 
repeated-measures variables also failed to produce a significant 
interaction or main effect involving test day (F1, 6=0.043, =0.984) or 
treatment (F1, 6=0.706, =0.433). Physiological measures (heart rate 
and blood pressure) did not differ in peak or baseline measures across 
treatment groups. 
 
Daily N-acetyl Cysteine Treatment Reduces Cocaine-
Induced Reinstatement in Rodents and Craving in 
Humans 
 
Figure 4 illustrates nonreinforced operant responding on the 
active lever during the last extinction session, reinstatement test 1 
(before N-acetyl cysteine treatment), or reinstatement test 2 (24 h 
after the last of seven daily N-acetyl cysteine treatments). An ANOVA 
comparing cocaine seeking with treatment (saline or N-acetyl cysteine) 
as a between-subject variable and experimental phase (extinction, 
reinstatement 1, or reinstatement 2) as a within-subject variable 
resulted in a significant interaction (F2, 46=4.08, =0.023). Post hoc 
comparisons indicated that cocaine seeking by the two groups of rats 
did not differ before N-acetyl cysteine treatment (eg, extinction 
responding or first reinstatement test); however, responding was 
significantly reduced during the second reinstatement test in rats that 
had received daily N-acetyl cysteine treatment (t-test, <0.05). 
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In cocaine-dependent human participants, N-acetyl cysteine 
significantly decreased craving reported after an injection of cocaine. 
An ANOVA comparing evoked craving with drug treatment as a 
between-subject factor and test day and phase of the experiment as 
repeated-measures variables produced a significant three-way 
interaction (F2, 12=14.5, =0.001). A post hoc comparison of the 
magnitude of craving reported following a cocaine injection on the first 
test day (before daily treatment with N-acetyl cysteine or baclofen) 
and the second test day (after daily drug treatment) indicated that 
daily N-acetyl cysteine, but not baclofen, produced a significant 
reduction in cocaine-induced craving (Figure 5; t-test, <0.05). 
 
Discussion 
 
The goals of this study were to further evaluate the therapeutic 
potential of N-acetyl cysteine treatment and, in doing so, examine the 
predictive validity of the reinstatement paradigm. Specifically, we 
studied the impact of repeated administration of N-acetyl cysteine on 
cocaine intake and cocaine-primed reinstatement in rodents and on 
self-reports of rush, high, and craving by nontreatment-seeking, 
cocaine-dependent human participants. The primary findings were that 
repeated N-acetyl cysteine lessened cocaine-induced increases in drug 
seeking in rats and craving in humans without altering the reinforcing 
effects of cocaine in rats and the euphoric properties of cocaine in 
humans. These findings further establish system xc– as a novel 
treatment for addiction, lend support for the use of the self-
administration/reinstatement paradigm as a model of aspects of 
addiction, and provide insight into why N-acetyl cysteine reduces drug 
use as revealed by earlier studies (Mardikian et al, 2007). 
 
Daily N-acetyl cysteine administration in this study significantly 
blunted cocaine-induced increases in extinguished drug seeking in 
rodents. There are several key points to emphasize from this novel 
data set. Specifically, neither repeated administration of N-acetyl 
cysteine nor a 24-h delay between the last dosing of N-acetyl cysteine 
and behavioral testing diminished the effectiveness of this drug in 
blocking cocaine-induced reinstatement that has been established in 
earlier studies utilizing acute administration immediately before testing 
(Baker et al, 2003, 2008; Kau et al, 2008). Furthermore, these data 
may indicate that reinstatement can be blocked by very low levels of 
N-acetyl cysteine or the accumulation of an active metabolite, such as 
cystine, as the half-life of systemic N-acetyl cysteine has been 
estimated to be 6.25 h (Olsson et al, 1988), although this was 
conducted in humans. Alternatively, repeated N-acetyl cysteine may 
have resulted in reduced reinstatement by masking or reversing 
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cocaine-induced plasticity that is necessary for cocaine reinstatement. 
This would extend our earlier observation that repeated N-acetyl 
cysteine treatment during self-administration training prevents the 
development of plasticity that is required for cocaine-induced 
reinstatement (Madayag et al, 2007). In support of the latter 
conclusion, repeated N-acetyl cysteine has been shown to produce an 
enduring suppression of cue- and heroin-induced reinstatement that 
persists for at least 40 days (Zhou and Kalivas, 2008). 
 
Daily N-acetyl cysteine administered to nontreatment seeking, 
cocaine-dependent participants reduced craving produced by a cocaine 
infusion. There are at least two interpretations of the data. First, the 
reduced craving observed on the second test session (eg, after N-
acetyl cysteine treatment) may have been because of an order effect 
as we lack a placebo group. However, we did not observe a change in 
cocaine-evoked craving in participants receiving baclofen. A more 
likely interpretation is that N-acetyl cysteine reduced craving produced 
by a cocaine injection. We also observed a reduction in craving 
produced by a cocaine video in subjects treated with N-acetyl cysteine, 
although the effect was not significant because of insufficient power. 
The lack of a significant change may be because of the preliminary 
nature of the clinical data arising from a lack of power. In support, an 
earlier report has observed that N-acetyl cysteine significantly reduces 
desire to use cocaine generated by a cocaine video (LaRowe et al, 
2007). Thus, the capacity of N-acetyl cysteine to reduce craving or 
desire to use cocaine following exposure to cocaine or cocaine-paired 
cues may provide insight into the observation of reduced cocaine use 
following repeated N-acetyl cysteine treatment (Mardikian et al, 2007). 
In addition to cocaine, N-acetyl cysteine has been shown to decrease 
tobacco use by smokers, reduce pathological gambling, and lessen 
other types of compulsive behaviors such as trichotillomania (Grant et 
al, 2007, 2009; Knackstedt et al, 2009). Although additional studies 
are needed to confirm these preliminary findings, the extant data 
support the potential for N-acetyl cysteine to reduce multiple types of 
addiction and other disorders of compulsive behavior.  
 
Repeated administration of N-acetyl cysteine in this study failed 
to alter the euphoric or reinforcing properties of cocaine as assessed in 
humans and rats, respectively. Because of the preliminary nature of 
the clinical experiment, it is possible that we lacked sufficient power to 
detect an impact of N-acetyl cysteine on the euphoric properties of 
cocaine in humans or that a higher dose of N-acetyl cysteine may have 
produced a more robust effect on these measures. However, at the 
very least, the human data indicate that cocaine-induced craving is 
more sensitive to the effects of repeated N-acetyl cysteine than the 
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euphoric properties of cocaine. Furthermore, the rodent data are 
consistent with our earlier data demonstrating that N-acetyl cysteine 
does not alter the acute effects of cocaine, such as drug self-
administration or cocaine-induced locomotor activity (Madayag et al, 
2007). Thus, the existing data pose an intriguing question regarding 
the use of N-acetyl cysteine as a treatment for addiction that merits 
further study. Specifically, is the value of a pharmacotherapy for 
addiction significantly diminished if the acute, euphoric properties of 
the previously abused drug persist in a manner that could maintain 
recreational drug use, provided there is a reduction in compulsive, 
uncontrollable drug use? 
 
An important goal of this translational study was to provide a 
preliminary assessment of the predictive validity of the reinstatement 
paradigm. There have been concerns raised regarding the number of 
apparent false positives whereby potential medications that block 
reinstatement fail to produce a positive effect in clinical trials. 
However, as has been noted in several excellent reviews, it is currently 
difficult to draw conclusions regarding the predictive validity of the 
reinstatement paradigm (Epstein and Preston, 2003; Epstein et al, 
2006; Yahyavi-Firouz-Abadi and See, 2009), in part because of the 
discrepancies of what is actually measured in preclinical reinstatement 
studies and clinical trials. Preclinical studies typically examine the 
capacity of acute administration of a putative medication to alter 
evoked drug seeking following exposure to a discrete stimulus, such as 
stress or a drug injection. In contrast, clinical trials often assess drug 
use following chronic administration of the medication. Thus, the key 
assumptions being made are that: (1) the effectiveness of a compound 
is not diminished following repeated administration, (2) the stimuli 
used to reinstate responding in rodents model aspects of addiction, 
such as craving, and (3) the phenomena being modeled, such as 
craving, actually contribute to continued drug use. In this study, we 
sought to deconstruct the numerous leaps between typical preclinical 
reinstatement studies and a clinical trial by more closely matching the 
outcomes assessed in rodents and humans. Specifically, we examined 
the capacity of repeated N-acetyl cysteine to alter evoked increases in 
reinstatement and craving (eg, change from baseline following a 
cocaine injection). Although the human data are preliminary and may 
lack sufficient power, our data indicate that N-acetyl cysteine failed to 
alter cocaine reinforcement in rodents and reward-based measures in 
humans, but significantly reduced cocaine-induced increases in drug 
seeking in rodents and craving in humans. Thus, the data appear to 
support the use of the reinstatement model as a drug screen for the 
development of medications to treat drug addiction. 
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Figure 1 Participants underwent phone and clinical interview/laboratory 
screening (S) before study enrollment (E). After 1 to 8 weeks, participants 
underwent a run-up procedure (R) to determine the safety of delivering 
cocaine (20 mg per 70 kg IV over 60 s). Afterwards, participants remained 
inpatient for 1 to 2 separate 4-day/3-night stays, each with one blinded, oral 
study medication: treatment A (oral N-acetyl cysteine; 400 or 800 mg TID) or 
B (oral baclofen; 20 mg TID). During each inpatient visit, the participant 
underwent a 1-h test session before and after drug treatment (pretest and 
posttest, respectively) while receiving a total of nine doses of the test 
medication during the 3 days between the two tests. Participants were 
discharged home on day 4, with some returning after a 7- to 14-day 
treatment washout period (W) for the second treatment arm of the study. 
After 12 to 16 days of the end of the final arm, participants returned for a 
discharge interview (DC) before study termination. 
 
 
 
Table 1 Baseline Measures of Craving, Rush, and High Collected 
Immediately Before Each Phase of the Experiment on Days 1 and 4 from the 
Baclofen and N-acetyl Cysteine-Treated Human Participants 
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Figure 2 Daily N-acetyl cysteine does not alter the amount of cocaine self-
administered by rats. Data depict the mean ± SEM number of infusions across 
12 maintenance self-administration sessions. Rats received N-acetyl cysteine 
(0 or 60 mg/kg, IP) 60 min before each session of cocaine self-administration 
(0.5 mg/kg, IV/infusion; 2 h/day; N=7/group). 
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Figure 3 Daily N-acetyl cysteine does not alter cocaine-induced rush (a) or 
high (b) in cocaine-dependent human participants. Data depict a change in 
self-reports (mean ± SEM) of rush and high from baseline values collected 
immediately before values obtained during exposure to a neutral video and 
cocaine video, or following a cocaine injection (20 mg/70 kg/60 s, IV). 
Measures of rush and high were obtained before and following daily baclofen 
(20 mg; TID; N=4) or N-acetyl cysteine (400 or 800 mg; TID; N=4) 
treatment. 
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Figure 4 Daily N-acetyl cysteine decreases cocaine-induced reinstatement in 
rodents. Data depict the mean (±SEM) number of lever presses over during 
the last extinction test, or during two reinstatement tests. Rats self-
administered cocaine (0.5 mg/kg/200 l IV; 2-h/day; N=10–12/group) over 
12 daily sessions. After 7 days of the last self-administration session, rats 
underwent daily extinction training in the absence of any drug treatment. This 
was followed by a test for cocaine-induced (10 mg/kg, IP) reinstatement. The 
day after the first reinstatement test, rats received seven daily injections of 
saline or N-acetyl cysteine (60 mg/kg, IP). The day after the seventh and 
final injection of saline or N-acetyl cysteine, rats underwent a second test for 
cocaine-induced reinstatement. #A significant difference from the first 
reinstatement test; t-test, <0.05. *A significant difference from extinction 
responding, <0.05. 
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Figure 5 N-acetyl cysteine reduces craving reported after a cocaine injection 
by human cocaine-dependent participants. Data depict a change in self-
reports (mean ± SEM) of craving from baseline values collected immediately 
before values obtained during exposure to a neutral video and cocaine video, 
or following a cocaine injection (20 mg/70 kg/60 s, IV). Measures of craving 
were obtained before and after daily baclofen (20 mg; TID; N=4) or N-acetyl 
cysteine (400 or 800 mg; TID; N=4) treatment. *A significant difference from 
craving reported following a cocaine injection on test day 1 (eg, pre-baclofen 
or N-acetyl cysteine treatment), <0.05, t-test. 
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